Disc Medicine Inc. (IRON)
NASDAQ: IRONHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IRON stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.42B
- EPS (TTM)
- -$6.34
- Dividend yield
- None
- 52-week range
- 40.00 – 99.50
- Day range
- 74.54 – 77.01
- Volume / Avg
- 561.64K / 951.56K
- Beta
- —
- Shares outstanding
- 45.54M
52-week range
IRON stock today
Disc Medicine (IRON) closed at $75.14 on Nov 20, down 1.27% (-$0.97), versus the S&P 500's 3.70% decline. At this level, IRON sits in the middle of its 52-week range of $40.00 to $99.50: 24.5% below the high, set on Dec 8, 2025 and 87.9% above the low. IRON is down 5.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 18.9%.
Disc Medicine has posted a net loss over the last twelve months (EPS of -$6.34), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Disc Medicine
Company profileDisc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. John D. Quisel Esq., J.D., Ph.D.
- Headquarters
- Watertown, MA
- Employees
- 173
- Website
- discmedicine.com
Financial highlights
Full financialsDisc Medicine reported a net loss of $212.2 million, compared with a loss of $109.4 million a year earlier. Diluted earnings per share came in at -$6.01.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-212.18M | $-109.36M | $-76.43M | $-46.83M | $-35.97M |
| EPS (diluted) | $-6.01 | $-3.96 | $-3.42 | $-45.05 | $-40.95 |
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$127.69+69.94%
- Strong buy 1
- Buy 12
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-1.53 vs $-1.65
- Surprise
- +7.27%
IRON news
All IRON news- Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business UpdateNasdaqIRON, BRK.B
- Disc Medicine GAAP EPS of -$1.53 beats by $0.20Seeking Alpha
- Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual MeetingGlobeNewswire
- Disc Medicine to Participate in Upcoming Investor ConferencesGlobeNewswire
- Weekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial WinNasdaqABBV, ABT, ACHV, ALVO
- Disc Medicine Consensus Price Target Increased by 12.67% to $118.56Nasdaq
- Disc Medicine, Inc. Closes Public Offering of 6,000,000 Shares of Common StockNasdaqIRON, MOG.B
Disc Medicine peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PBLSParabilis Medicines Inc. | 27.44 | -0.67% | $3.44B | vs IRON |
| ELVNEnliven Therapeutics Inc. | 46.53 | +0.26% | $3.42B | vs IRON |
| VRDNViridian Therapeutics Inc. | 29.96 | -4.71% | $3.40B | vs IRON |
| AMLXAmylyx Pharmaceuticals Inc. | 26.02 | -0.69% | $3.35B | vs IRON |
| ARQTArcutis Biotherapeutics Inc. | 26.36 | -2.98% | $3.33B | vs IRON |
| XENEXenon Pharmaceuticals Inc. | 37.04 | -1.38% | $3.64B | vs IRON |
| OGNOrganon & Co. | 13.89 | -0.14% | $3.65B | vs IRON |
| TNGXTango Therapeutics Inc. | 21.73 | -4.32% | $3.68B | vs IRON |
Indexes, lists and sector
Disc Medicine stock FAQ
What is Disc Medicine's stock price today?
IRON last traded at $75.14 as of Nov 20, 4:00 PM EST, down 1.27% on the day. Prices are delayed at least 15 minutes.
Does Disc Medicine pay a dividend?
No. Disc Medicine does not currently pay a regular cash dividend.
Who is Disc Medicine's CEO?
Dr. John D. Quisel Esq., J.D., Ph.D. is the chief executive officer of Disc Medicine Inc., which has about 173 employees.
Has IRON ever split its stock?
Yes. The most recent IRON stock split was a 1-for-30 split on Dec 30, 2022.
What is the IRON 52-week high?
The 52-week high for IRON is $99.50 and the 52-week low is $40.00. The stock is currently 24.5% below its high.